الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 205 |  |  |
| | | from | 205 | | |
Abstract
Hepatocellular carcinoma (HCC) is the fifth most common malignant tumor all over the world. Although several treatments such as tumor resection and liver transplantation are used to treat HCC, there is no overall long-term survival benefit. Therefore, the need for therapy to prevent the recurrence of HCC is essential. Curcumin and taurine have been used to participate in cancer management such as HCC through activation of immune system. Mononuclear leukocytes (MNLs) obtained from cirrhotic patients (25), HCC patients (25) and healthy volunteers (25) were included in this study. Then the isolated MNLs were treated with curcumin and taurine, cell density, IFN-γ level, and expression of CD4+, CD8+, and CD25+ were performed. The results revealed that there was highly significant increase in MNLs density of cirrhotic patients treated with curcumin and taurine. where in HCC patients there were high significant increases in MNLs treated with curcumin and/ or taurine. IFN-γ level showed no significant increase in HCC, cirrhotic patients and controls. There were high significant increases in CD8+ of cirrhotic and HCC patients treated with curcumin and combination of curcumin and taurine. But, CD4+ showed high significant decrease in cirrhotic treated with curcumin and combination of curcumin and taurine and in HCC patients due to treatment with curcumin and/ or taurine; on the contrary there were high significant increases in controls. Furthermore, there were high significant increases in CD25+ of cirrhotic patients and healthy controls treated with curcumin and/ or taurine, but in HCC patients showed no significant increase in CD25+ in MNLs treated with curcumin and/or taurine.